A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jan 29, 2018

Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium

– A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions –

TOKYO – January 26, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data to be presented at the 2018 Genitourinary Cancers...

Read more about Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium
Jan 24, 2018

Astellas Completes Acquisition of Mitobridge, Inc.

Tokyo, Janurary 24, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Mitobridge, Inc....

Read more about Astellas Completes Acquisition of Mitobridge, Inc.
Jan 23, 2018

Astellas Receives Orphan Designation from the European Commission for Gilteritinib for the Treatment of Acute Myeloid Leukaemia

TOKYO – January 23, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the European Commission (EC) has issued Orphan...

Read more about Astellas Receives Orphan Designation from the European Commission for Gilteritinib for the Treatment of Acute Myeloid Leukaemia
Jan 22, 2018

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

TOKYO and SAN DIEGO – Jan. 22, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ: VICL) announced today that...

Read more about Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
Jan 12, 2018

Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more about Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan
Jan 11, 2018

Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of Selective SGLT2 Inhibitor Ipragliflozin L-Proline for Patients with Type 1 Diabetes Mellitus in Japan

Tokyo and City, January 11, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) and Kotobuki Pharmaceutical Co., Ltd. (President and CEO; Hiroshi...

Read more about Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of Selective SGLT2 Inhibitor Ipragliflozin L-Proline for Patients with Type 1 Diabetes Mellitus in Japan
Jan 9, 2018

Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE® ) Antibody Construct Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Japan

TOKYO (January 9, 2018) - Amgen Astellas BioPharma K.K. (Headquarters Tokyo; President and Representative Director Steve Sugino “Amgen Astellas BioPharma”) and Astellas Pharma Inc....

Read more about Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE® ) Antibody Construct Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Japan
Dec 20, 2017

Astellas to Present at J.P. Morgan Healthcare Conference

Tokyo, December 20, 2017 - Astellas Pharma Inc. today announced that the company's President and CEO Yoshihiko Hatanaka will present at the 36 th Annual J.P. Morgan Healthcare Conference on...

Read more about Astellas to Present at J.P. Morgan Healthcare Conference
Dec 11, 2017

Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

TOKYO – December 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the first reported data of the investigational agent...

Read more about Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia
Dec 6, 2017

Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice”

Tokyo, December 6, 2017 - Astellas Pharma Inc. (Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas” ), the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori...

Read more about Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice”

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts